Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models

Abstract

Using preclinical TNBC models that recapitulate the breast tumor microenvironment, we demonstrate that cabozantinib inhibition is an effective therapeutic strategy in several TNBC subtypes.